Buying Optionality: A Speculative Swing Trade on Innate Pharma (IPHA)
Innate Pharma (IPHA) trades at roughly $168M market cap with multiple clinical-stage assets in oncology. The shares sit near $1.75 after pulling back from a $2.62 52-week high; average volumes are low and short interest has been meaningful. For traders willing to accept binary clinical and financing risk, a controlled long swing (mid term, 45 tradi…